KALA BIO, Inc. (NASDAQ:KALA) Given Consensus Rating of “Hold” by Analysts

KALA BIO, Inc. (NASDAQ:KALA) has received a consensus rating of “Hold” from the six research firms that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and one has assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $20.3750.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of KALA BIO in a research note on Monday, December 29th.

Institutional Trading of KALA BIO

Several institutional investors and hedge funds have recently modified their holdings of the company. AIGH Capital Management LLC lifted its stake in shares of KALA BIO by 52.8% during the 2nd quarter. AIGH Capital Management LLC now owns 300,000 shares of the company’s stock valued at $1,428,000 after buying an additional 103,650 shares in the last quarter. Woodline Partners LP purchased a new stake in KALA BIO in the 1st quarter worth $1,483,000. Geode Capital Management LLC raised its holdings in KALA BIO by 2.8% during the second quarter. Geode Capital Management LLC now owns 56,367 shares of the company’s stock valued at $268,000 after acquiring an additional 1,534 shares during the period. Finally, XTX Topco Ltd purchased a new position in shares of KALA BIO in the second quarter valued at about $62,000. 24.61% of the stock is currently owned by institutional investors.

KALA BIO Stock Performance

Shares of KALA BIO stock opened at $0.44 on Thursday. The stock has a market cap of $4.33 million, a P/E ratio of -0.07 and a beta of -2.43. The stock’s fifty day moving average is $0.67 and its 200 day moving average is $4.52. KALA BIO has a one year low of $0.41 and a one year high of $20.60.

KALA BIO (NASDAQ:KALA) last issued its quarterly earnings results on Wednesday, November 19th. The company reported ($1.07) EPS for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.06). Analysts predict that KALA BIO will post -10.84 EPS for the current year.

KALA BIO Company Profile

KALA Bio (NASDAQ: KALA) is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for ocular diseases. The company’s proprietary surface charge–based nanoparticle delivery platform is designed to enhance penetration and retention of therapeutic agents on the ocular surface. This technology is the basis for its lead product, Eysuvis (KPI-121 1.0%), an FDA-approved topical corticosteroid for short-term relief of ocular itching associated with allergic conjunctivitis.

Beyond its approved therapy, KALA Bio is advancing a pipeline of investigational drug candidates targeting inflammatory and degenerative eye conditions.